Thelansis’s “Global Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Pulmonary Fibrosis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown aetiology, characterised by aberrant epithelial injury responses, fibroblast activation, and excessive extracellular matrix deposition — producing the pathological hallmark of usual interstitial pneumonia (UIP) — resulting in irreversible destruction of lung architecture and progressive respiratory failure. Genetic susceptibility variants, particularly MUC5B promoter polymorphisms, alongside ageing, cigarette smoking, gastro-oesophageal reflux, and occupational dust exposures are recognised risk determinants. Patients — predominantly older males — present insidiously with progressive exertional dyspnoea, dry cough, and bibasal inspiratory velcro-like crackles, with clubbing present in a significant proportion. Diagnosis integrates high-resolution CT demonstrating characteristic UIP pattern — subpleural, basal-predominant honeycombing with or without traction bronchiectasis — alongside pulmonary function testing revealing restrictive physiology and reduced DLCO; surgical lung biopsy is reserved for diagnostically uncertain cases. Antifibrotic therapies — nintedanib and pirfenidone — slow FVC decline and disease progression but do not reverse established fibrosis. Lung transplantation remains the only potentially life-extending intervention in eligible patients. Pulmonary rehabilitation, supplemental oxygen, and proactive management of comorbidities — including pulmonary hypertension and acute exacerbations — are essential. Prognosis remains poor with median survival of two to five years; early palliative integration, advance care planning, and compassionate patient-centred support are indispensable throughout the disease trajectory.
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Global Idiopathic Pulmonary Fibrosis (IPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report
Our team will get in touch with you shortly about the Global Idiopathic Pulmonary Fibrosis (IPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report.